Needham analyst Michael Matson (NYSE:MATX) maintained a Buy rating on OrthoPediatrics (NASDAQ:KIDS) Corp on Wednesday, setting a price target of $83, which is approximately 41.78% above the present share price of $58.54.
Matson expects OrthoPediatrics Corp to post earnings per share (EPS) of -$0.19 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in OrthoPediatrics, with an average price target of $77.4.
The analysts price targets range from a high of $83 to a low of $69.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $26.7 million and a net profit of -$2.85 million. The company's market cap is $1.15 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.7% and a 60.54% success rate.
OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.